John Frantzis

John Frantzis joined the AVG team as a consulting commercial advisor and will join AVG officially as Chief Business Development Officer pursuant to closing this round. John brings extensive experience in a wide range of innovative sales, marketing and business development strategies for the Biotechnology, Pharmaceutical and Medical Devices and Medical Digital AI technology space. John has a significant track record in commercial execution in addition to being responsible for one of the largest transactions in Laser Vision Correction history with the acquisition of Summit lasers by Alcon.

John has more than 25 years of executive management experience in emerging technology in the Biotech/ Pharma space. He has a highly successful record of achievement, which includes a proven track record and demonstrated effectiveness in a high growth, results-driven environments. Recently having a 400 million exit at Avedro. Acquired by Glaukos while running Worldwide Sales. Recently helping Heru www.seeheru.com raise 30 million from D1 capital. Also consulting to Toku Eyes raising capital and working with Global KOL’s in the retina space on an AI platform technology.

Was VP of Global Sales and BD, lead the worldwide launch of ophthalmic crosslinking products at Avedro, As Vice President of Business Development and Global Sales for NDO surgical, Mr. Frantzis has been leading the company’s worldwide commercial organization, business development and partner programs. As Executive Vice President and Business Development for Summit Technology, from 1990 to 1997, John established and managed its sales teams and distribution organization in more than forty countries, growing revenue from $1 to $160 million during his tenure, with an exit of 1 billion. He developed a comprehensive strategic business plan for the company, including strategic market direction, infrastructure requirements, to position the company for substantial growth establishing the laser vision correction market.